Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
Week ahead: 3 health care IPOs set to price during the week of September 14
Analyst IPO Market Commentary
After three weeks without any deals, the US IPO market is back in session.
Three health care companies are each set to raise about $100 million in the
Backed by Fidelity, medical device company
) boasts strong sales growth (+41% in the 1H15) and near-profitability as it looks to ramp up its sales force. Its proposed $847 million market cap would make it the year's largest medical products company to go public, and its valuation is being pitched below its peer group.
) has the profile of a biotech with strong first-day pop potential. The company owns the rights to a gene therapy delivery technology used by eight partners developing 18 drug candidates, including Baxalta, Dimension (
) and Voyager. It is also well-funded, snagging $71 million in May from notable investors including Janus, Venrock, Deerfield, GSK, Fidelity and Vivo Capital. However, its drug pipeline is entirely preclinical and its patents begin expiring in 2022. Lead underwriter Morgan Stanley has led two biotech IPOs this year, most recently Global Blood Therapeutics (
; +164%) in August.
) is looking to raise $96 million at a much lower valuation. The company is set to begin Phase 3 trials for a new class of antibiotics aimed at treating pneumonia, with a lead candidate designated by the FDA for Fast Track review. Approval would still be a few years out, and the therapy would face significant competition from generics. Nabriva raised $50 million in April from Vivo Capital, OrbiMed, Novartis and others, and insiders plan to purchase an additional $50 million worth of shares on the offering, or 52% of the proposed deal size.
We note that the 2015 IPO market has been marked by a
scarcity of technology companies
and an abundance of health care, primarily biotechs. The VIX Volatility Index finished Friday below 25 and hit its lowest level since the market sell-off in mid-August, a welcome sign for the numerous IPOs waiting in the wings. However, zero IPOs filed terms on Monday morning; companies are likely waiting for valuation multiples to expand (the average 2015 non-biotech IPO is up just 2%) and for markets to react to the Fed's rate hike decision (
Digicel, for example
) before moving forward.
Renaissance Capital's IPO Calendar - Week of 9/14/2015
$25 - $28
BofA Merrill Lynch
Markets devices for neuro and peripheral vascular conditions and diseases.
$17 - $19
BofA Merrill Lynch
Developing gene therapies for rare diseases with a proprietary delivery platform.
$15 - $17
RBC Capital Markets
Developing a novel antibiotic for bacterial pneumonia.
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO pipeline update: Just 3 initial filings, but others in the pipeline get ready
As we highlighted in our 2015 Fall IPO Preview, the active pipeline contains a high number of LBOs and health care companies. Two preclinical biotechs and one LBO submitted initial filings in the past week. Acquired by Goldman and Olympus Partners in 2014,
) is the largest provider of audiovisual and technology set-up services for events with $1.4 billion in sales. Backed by Frazier and Novo Ventures,
) is looking to raise $86 million as it develops therapies for severe asthma and peanut allergies. Gene therapy biotech
) filed on Monday for an IPO that could raise $115 million. Other companies have been gearing up for fourth quarter IPOs with updated filings. Highly-anticipated tech IPO
) updated its financial results,
Performance Food Group
) amended its filing and
), which could be the year's largest IPO, selected a ticker and exchange. In addition, five biotechs submitted amended filings, each one seeking to raise over $80 million.
IPO Market Snapshot
Strong IPO volume in the fourth quarter will in part hinge on improved returns for recent IPOs. The Renaissance IPO Index has traded down 7.3% year-to-date, compared to -5.1% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Hilton Worldwide (
) and Twitter (
). In the past month, Alibaba and Twitter fell below their IPO prices for the first time. The Renaissance International IPO Index has traded down 1.6% year-to-date, compared to -6.3% for the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Recruit Holdings and Cheil Industries. In May 2015, the US IPO Index was up 9% year-to-date and the International IPO Index was up 15%.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.